MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

39.78 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗
Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗
Hims & Hers stock traded more than 40% higher after the deal was announced. 
Via The Motley Fool
Topics Lawsuit
News headline image
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗
The price of the company's popular GLP-1 drugs could come down by as much as 50% next year. 
Via The Motley Fool
News headline image
Hims & Hers Stock Pops 40%: Everything You Need to Know ↗
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk. 
Via The Motley Fool
Topics Lawsuit
News headline image
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗
Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗
They may appeal to different kinds of investors. 
Via The Motley Fool
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
These companies have a lot more to offer than their prospects in the weight loss market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗
Things can't get that much worse for the drugmaker. 
Via The Motley Fool
News headline image
Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗
According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare. 
Via Stocktwits
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗
Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility. 
Via The Motley Fool
News headline image
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗
Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations. 
Via The Motley Fool
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗
The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs. 
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Unexpected Stock Picks and Looking to the Future ↗
Why does the shortest month of the year sometimes feel like the longest? 
Via The Motley Fool
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
The stock is down big of late, but the business is by no means doomed. 
Via The Motley Fool
Topics Intellectual Property
MarketBeat Week in Review – 02/23 - 02/27 ↗
Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets... 
Via MarketBeat
News headline image
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional... 
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising. 
Via The Motley Fool
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
The maker of Wegovy hasn't said its last words just yet. 
Via The Motley Fool
News headline image
Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures. 
Via The Motley Fool
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think. 
Via The Motley Fool
News headline image
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026. 
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story